Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

The American Journal of Cardiology
Christie M BallantyneHarold E Bays

Abstract

Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein cholesterol (LDL-C) levels in patients with hypercholesterolemia. In this 24-week, multicenter, double-blind, placebo-controlled, dose-ranging study (NCT01592240), subjects with LDL-C levels≥80 mg/dl on stable statin therapy were randomized to Q14 days subcutaneous placebo or bococizumab 50, 100, or 150 mg or Q28 days subcutaneous placebo or bococizumab 200 or 300 mg. Doses of bococizumab were reduced if LDL-C levels persistently decreased to ≤25 mg/dl. The primary end point was the absolute change in LDL-C levels from baseline to week 12 after placebo or bococizumab administration. Continuation of bococizumab administration through to week 24 enabled the collection of safety data over an extended period. Of the 354 subjects randomized, 351 received treatment (placebo [n=100] or bococizumab [n=251]). The most efficacious bococizumab doses were 150 mg Q14 days and 300 mg Q28 days. Compared with placebo, bococizumab 150 mg Q14 days reduced LDL-C at week 12 by 53.4 mg/dl and bococizumab 300 mg Q28 days reduced LDL-C by 44.9 mg/dl; this was despite dos...Continue Reading

References

Jul 4, 2001·Clinical Chemistry and Laboratory Medicine : CCLM·H ScharnaglW März
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Nov 21, 2008·Journal of Lipid Research·Jay D HortonHelen H Hobbs
Jul 9, 2010·Clinical Pharmacology and Therapeutics·N HolfordB A Ploeger
Nov 2, 2012·The New England Journal of Medicine·Eli M RothEvan A Stein
Feb 5, 2013·The American Journal of Cardiology·John C LaRosaScott M Wasserman
Nov 19, 2013·JAMA : the Journal of the American Medical Association·Seth S MartinSteven R Jones
Apr 1, 2014·The New England Journal of Medicine·Dirk J BlomUNKNOWN DESCARTES Investigators
Apr 3, 2014·Journal of the American College of Cardiology·Michael J KorenUNKNOWN MENDEL-2 Investigators
Jun 25, 2014·Nature Reviews. Cardiology·Razvan T Dadu, Christie M Ballantyne
Apr 18, 2015·Journal of the American College of Cardiology·Sripal BangaloreUNKNOWN TNT Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Apr 26, 2018·Mini Reviews in Medicinal Chemistry·Yan Wang, Zhao-Peng Liu
May 18, 2016·EMBO Molecular Medicine·Thorsten KesslerHeribert Schunkert
Oct 18, 2016·Current Opinion in Cardiology·Alon Eisen, Robert P Giugliano
Feb 6, 2016·Current Opinion in Lipidology·Daniel Gaudet
Feb 10, 2016·Current Opinion in Endocrinology, Diabetes, and Obesity·Evan A Stein
Sep 19, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ellen Q WangDaniel Baltrukonis
Mar 16, 2017·Journal of Internal Medicine·A G OlssonL Yvan-Charvet
Sep 20, 2015·Current Cardiology Reports·Evan A Stein, Frederick J Raal
Jan 1, 2016·Lipids in Health and Disease·Maciej BanachAdrian Covic
Jan 19, 2016·Current Opinion in Lipidology·M John ChapmanUNKNOWN PCSK9 Forum
May 6, 2016·Annual Review of Nutrition·Erin E MulvihillMurray W Huff
Jul 9, 2016·Current Opinion in Lipidology·Bryce Chackerian, Alan Remaley
May 25, 2016·Current Cardiology Reports·Michel Farnier
Dec 14, 2016·The New England Journal of Medicine·Kevin FitzgeraldAmy Simon
Apr 30, 2017·The Cochrane Database of Systematic Reviews·Amand F SchmidtJuan P Casas
Apr 21, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Belinda Di BartoloStephen J Nicholls
Jun 16, 2017·Expert Opinion on Biological Therapy·Giacomo PucciGiuseppe Schillaci
May 21, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kristopher J Swiger, Seth S Martin
Jun 17, 2015·Nature Reviews. Cardiology·Željko Reiner
Jan 5, 2016·European Heart Journal·M John ChapmanUlf Landmesser
Aug 24, 2016·Expert Review of Cardiovascular Therapy·Maria DrakopoulouDimitrios Tousoulis
Mar 18, 2016·Pharmacological Reviews·Philip J Barter, Kerry-Anne Rye
Sep 16, 2015·Clinical Pharmacology and Therapeutics·E Yang
Dec 28, 2016·Diabetologia·David Preiss, Marion Mafham
Dec 15, 2015·MAbs·Janice M Reichert
Apr 4, 2017·Expert Opinion on Investigational Drugs·Gerald H Tomkin, Daphne Owens
Dec 11, 2017·Journal of the American Heart Association·Aris KaratasakisEmmanouil S Brilakis
Mar 9, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Yang WangShenming Wang
Jul 1, 2020·Expert Review of Clinical Pharmacology·F H van BruggenHendrika Luijendijk
May 20, 2016·Journal of Clinical Pharmacology·Matthew K Ito, Raul D Santos
Jan 30, 2016·Expert Opinion on Biological Therapy·Marcos G ValerioWilbert S Aronow
Oct 13, 2015·BMC Medicine·Robert M StoekenbroekRoeland Huijgen
Jul 17, 2016·Postgraduate Medicine·Marc S SabatineSeth J Baum
Dec 9, 2016·Expert Opinion on Emerging Drugs·Marie-Jeanne Bertrand, Jean-Claude Tardif

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Related Papers

© 2021 Meta ULC. All rights reserved